{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s', 'Description of Change', 'Rationale for the Change', 'CCI', 'Section 2:Protocol Synopsis', '1) Removed the secondary OS1 objective/endpoint.', '1) OS1 is now considered as a sensitivity', 'Section 5.1.2:Secondary', 'CCI', 'analysis of OS, in which patients will be', 'Objectives', 'censored at the date of first dose of the', 'new anti-MM treatment.', 'Section 5.2.2: Secondary Efficacy', 'Endpoints (new subsection)', '2) To align with the SAP.', 'Section 5.2.2.2: Non-Key', 'Section 5.1.2 Secondary Objectives', 'Secondary Efficacy Endpoints', '(new subsection)', 'To compare the DOR in patients randomized to', 'Section 13.5.2: Analyses of the', 'the SVd Arm versus the Vd Arm', 'Key Secondary Endpoints (new', 'To compare OS in patients randomized to the SVd', 'subsection)', 'Arm versus patients randomized to the Vd Arm', 'Section 13.5.3: Analyses of the', 'who do not cross over to SVdX or SdX (Vd', 'Non-Key Secondary Efficacy', 'patients who cross over will be censored at the', 'Endpoints', 'date of crossover) (OS1)', 'CCI', 'To compare ORR, PFS, and DOR for patients', 'with 1 prior anti MM regimen versus > 1 prior', 'anti MM regimen in patients randomized to the', 'SVd Arm versus the Vd Arm', 'Confidential', 'Page 120', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'CCI', 'Section 2: Protocol Synopsis', 'Revised the definition of DOR to specify \"IRC-', 'To align with the SAP', 'Section 5.2.2.2: Non-Key', 'confirmed\" response and death \"due to any cause.\"', 'Secondary Efficacy Endpoints', 'DOR, defined as the duration of time from first', '(new subsection)', 'occurrence of IRC-confirmed response > PR until the', 'first date of IRC-confirmed PD or death due to any', 'cause, whichever occurs first', 'CCI', '1) These endpoints are discussed in the SAP', 'as subgroup analyses of PFS and ORR but', 'are not considered to be separate', 'endpoints.', '2) To align with the more accurate language in', 'the SAP.', 'Confidential', 'Page 121', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Section(s)', 'Description of Change', 'Rationale for the Change', 'Section 2: Protocol Synopsis', 'Revised the basis for the determination of R-ISS stage', 'To provide the correct basis for determination', 'Section 6.1: Overall Study Design', 'used in stratification of randomization from \"at original', 'of R-ISS stage.', 'and Plan', 'MM diagnosis\" to \"at study entry, based on screening', 'results.\"', 'Section 8.2: Randomization to', 'Study Treatment', 'Section 8.2 Randomization to Study Treatment', 'Randomization will be stratified based on the following', 'stratification factors and will maintain the 1:1 allocation', 'between treatment arms (SVd, Vd) within each of the', 'stratification categories:', 'Prior PI therapies (Yes or No)', 'Number of prior anti-MM regimens (1 versus >1)', 'Confidential', 'Page 122', 'Version 4.0']\n\n###\n\n", "completion": "END"}